Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Title: Patient insights expand understanding of APDS Presenting Author: Kristie Cline, MBA, Pharming Healthcare, Inc., Warren, NJ, USA Session Type: Poster Session Date/Time: Saturday, May 3, 2025, ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.